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Abstract
A 23-year-old, white male metallurgist presented with
pruritic erythematous maculo-papules over the trunk
and upper limbs and 6 months later developed erythro-
derma, eosinophilia and multi-organ dysfunction. A
diagnosis of chronic eosinophilic leukaemia was made
on the basis of myeloproliferative involvement of both
peripheral blood and bone marrow, associated with eo-
sinophilic differentiation and a t(5;12)(q33;p13) translo-
cation. The initial therapeutic approach was interferon
alfa-2b plus cytosine arabinoside, for 13 months, fol-
lowed by hydroxyurea plus vincristine. There was im-
provement of skin lesions, disappearance of eosinophilia
and decrease of serum immunoglobulin E, towards nor-
mal values.
Copyright © 2002 S. Karger AG, Basel
Introduction
The idiopathic hypereosinophilic syndrome (HES) has
been defined as a disease characterized by unexplained
eosinophilia (greater than 1.5 ! 109/l) persisting for at
least 6 months and leading to organ damage. The diagno-
sis of HES is usually based on the exclusion of any
underlying disease that could be responsible for the eosin-
ophilia and the lack of any evidence of clonality of
myeloid cells. At present there is accumulating evidence
that many cases that were previously considered as HES
are either reactive conditions or clonal eosinophilic disor-
ders [1–4].
Persistent reactive eosinophilia may occur in a number
of disease states including allergy, parasitic infections and
neoplastic conditions. Accordingly, reactive eosinophilia
has been reported in various skin diseases (eczema, der-
matitis, drug reactions), malignancies (Hodgkin’s disease,
T-cell lymphoma, lung cancer), chronic granulomatous
diseases (tuberculosis), fungal infections (coccidioidomy-
cosis, aspergillosis) and drug reactions [5].
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A distinct myeloproliferative disorder characterized by
prominent eosinophilic differentiation is currently recog-
nized, and usually designated as chronic eosinophilic leu-
kaemia (CEL) [1]. Accumulating evidence suggests that
CEL is not a single disease, but comprises a variety of dif-
ferent myeloproliferative disorders (MPD), which have in
common the proliferation of a neoplastic clone of cells
with prominent eosinophilic differentiation. These in-
clude chronic myelomonocytic leukaemia with eosino-
philia (CMML-Eo) and chronic myelomonocytic leu-
kaemia with eosinophilia and evolution into acute my-
eloid leukaemia and T-lineage lymphoblastic lymphoma
(CMML-Eo/AML/T-ALL) [4]. Interestingly, specific
chromosomal aberrations have been related to CEL syn-
dromes. CMML-Eo is frequently associated with the
t(5;12)(q33;p13) and other translocations involving chro-
mosome 5q31–35 [6–8] whereas CMML/Eo/AML/T-
ALL cases have been associated with t(8;13)(p11;q12)
and other cytogenetic abnormalities involving chromo-
some 8p11–12 [9, 10]. Other chromosomal abnormalities
that have been occasionally associated with CEL are
t(8;9)(p22;p23) [11], t(3;9;5)(q25;q34;q33) [12] and tri-
somy 15 [3]. In some of the reported cases, the molecular
mechanisms involved in the translocations have been
identified [13–17]. Eosinophilia may also occur in other
clonal stem cell disorders, such as other specific chronic
myeloproliferative disorders, myelodysplastic syndromes
and acute myeloid leukaemia. Once again, recurrent chro-
mosomal translocations have been documented in these
patients, suggesting that eosinophilic differentiation oc-
curs as a consequence of certain specific cytogenetic
abnormalities [3, 18].
From a clinical point of view, the differential diagnosis
between HES and CEL is not always clear. Patients with
CEL more frequently display hepatosplenomegaly, which
might be associated with neutrophilia, monocytosis,
anaemia, thrombocytopenia or trilineage myelodysplasia.
Neutrophil alkaline phosphatase is often reduced and
transformation into an acute leukaemia has been reported
in some patients [8].
Although present in CEL, erythroderma may also be a
manifestation of allergy, parasitic infection and non-hae-
mopoietic malignant conditions [19].
Herein, we describe a patient with a past history sug-
gestive of allergy who presented with erythroderma, leu-
cocytosis with mild eosinophilia, increased IgE and or-
ganomegaly, and whose cytogenetic findings established
the diagnosis of a CEL. To the best of our knowledge, this
is the first case in whom an association of erythroderma,
increased IgE, eosinophilia and a clonal myeloprolifera-
tive disorder with eosinophilic differentiation has been
reported.
Case Report
A 23-year-old white male metallurgist was referred to the Derma-
tology Department of Hospital Sa˜o Joa˜o (Porto, Portugal) in April
1998 because of persistent pruritic erythematous maculo-papules
over the trunk and upper limbs; these had been present for 1 year.
Full blood counts were: WBC 34.0 ! 109/l, haemoglobin (Hb)
12.6 g/dl; platelets 137 ! 109/l (with platelet clumps). The patient
was started on prednisolone, 40 mg/day, per os, with gradual tapering
till December 1998.
At this stage, he was referred to the Haematology Department,
because of generalized skin lesions and organomegaly. He com-
plained of pruritus and dry eyes and physical examination showed
extensive maculopapular skin lesions and generalized exfoliative
erythroderma, keratoconjunctivitis sicca, periocular xanthomas,
deep subcutaneous cervical induration, generalized lymphadenopa-
thy and enlarged liver and spleen. Ophthalmologic examination
revealed bilateral perilimbic infiltration. Skin prick tests were strong-
ly positive for house dust mite. A presumptive diagnosis of contact
dermatitis was made, based solely upon an occupational history of
handling of chromium products, given the infeasibility of skin con-
tact tests with these specific materials. His full blood count was:
WBC 14.0 ! 109/l, neutrophils 6.2 ! 109/l, eosinophils 1.5 ! 109/l,
basophils 0.28 ! 109/l, lymphocytes 4.2 ! 109/l, monocytes 0.14 !
109/l, metamyelocytes 0.14 ! 109/l, red cell count 3.55 ! 1012/l, Hb
11.1 g/dl, reticulocytes 4%, platelets 200 ! 109/l, erythrocyte sedi-
mentation rate 98 mm. Neutrophil alkaline phosphatase activity was
decreased. Serum IgE levels were markedly increased: 3,003 kU/l
(normal range: !114 kU/l), while other serum immunoglobulins
were: IgG 1,810 mg/dl (normal range: 650–1,500 mg/dl); IgA
604 mg/dl (normal range: 78–312 mg/dl); IgM 192 mg/dl (normal
range: 55–300 mg/dl); kappa light chains 607 mg/dl (normal range:
200–440 mg/dl); lambda light chains 296 mg/dl (normal range: 110–
240 mg/dl). Circulating immune complexes were mildly elevated:
4.7 Ìg/dl (normal range: !3.3 Ìg/dl).
The bone marrow aspirate and trephine biopsy showed marked
hypercellularity and very striking granulocytic and eosinophilic hy-
perplasia, increased mast cells and increased megakaryocytes which
were pleomorphic and dysplastic. Both skin and lymph node biopsies
showed eosinophilic infiltration.
A flow cytometric study of peripheral blood T lymphocytes based
on four-colour staining with a large panel of monoclonal antibodies
against various T-cell-associated antigens did not reveal any immu-
nophenotypic abnormality that would have suggested a clonal T-cell
disorder. The immunophenotypic analysis study of the TCR Vß
repertoire and the molecular study of the TCRß gene similarly
excluded this possibility.
Immunophenotypic studies confirmed the presence of eosino-
phils in the peripheral blood, which represented 18.4% of the total
leucocytes. Like normal eosinophils, these cells showed marked
green-to-red autofluorescence and were positive for CD13+,
CD33+dim, CD65+, CD11b+ and CD15+ myeloid-associated anti-
gens; they coexpressed the CD38+dim and CD45+. In contrast, they
lacked reactivity for CD2, CD3 (both membrane and cytoplasmic),
CD4, CD5, CD7, CD8, CD10, CD19, CD20 and CD79a lymphoid-
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Fig. 1. G-banded karyotype of bone marrow
cells showing 46,XY,t(5;12)(q33;p13).
related antigens and markers associated with cell immaturity (CD34,
HLA-Dr and terminal deoxynucleotidyl transferase). Other myeloid
antigens (MPO, CD14, CD61, glycophorin A) were negative. This
phenotype is identical to that usually reported for normal peripheral
blood eosinophils.
Chromosomal analysis, carried out after short-term culture of
bone marrow cells, showed 46 XY, t(5;12)(q33;p13) [2], 46 XY [2]
(fig. 1); t(9;22) was excluded by RT-PCR using specific primers for
the BCR and ABL genes. t(5;12) has been reported to fuse the TEL/
ETV6 gene at 12p13 to PDGFßR at 5q33 [13]. We tested whether
PDGFßR was also involved in this case by interphase FISH using
flanking cosmid probes as previously described [20]. Of 73 evaluable
interphase cells analysed, 50 (68%) showed one fused signal and sep-
arated red and green signals confirming that the PDGFßR gene was
indeed disrupted.
Based on the cytogenetic findings, a diagnosis of CEL was made
and the patient was started on interferon alfa-2b (7,500,000 units 3
times/week) plus cytosine arabinoside (20 mg daily subcutaneous).
This therapeutic approach was successful in decreasing the WBC
count and peripheral blood neutrophilia, eosinophilia and basophil-
ia, and the bone marrow hypercellularity; there was also a reduction
in the hepatomegaly, splenomegaly and lymphadenopathy. How-
ever, by July 1999, during the course of this therapy, large nodules
had appeared on his face (2 ! 1 cm) and forearms (3 ! 4 cm); pred-
nisolone (40–80 mg every second day per os) was then added. After
12 months of therapy, the patient still had skin lesions, increased IgE
and circulating immune complexes. He was then started on hydroxy-
urea (1,000 mg/day per os) plus vincristine (2 mg i.v., days 1 and 8 of
28), which was efficacious in controlling the eosinophilia and amelio-
rated organ infiltration; the facial skin infiltration lessened as did the
periocular xanthomas. After 5 months of therapy, organomegaly was
no longer detectable.
At that time, his laboratory results were as follows: WBC 2.8 !
109/l (neutrophils 1.74 ! 109/l, eosinophils 0.07 ! 109/l, basophils
0.02 ! 109/l, lymphocytes 0.77 ! 109/l, monocytes 0.16 ! 109/l),
serum IgE 1,149 kU/l, IgG 1,730 mg/dl, IgA 732 mg/dl and IgM
111 mg/dl. A bone marrow aspirate (while on hydroxyurea) showed a
marked improvement in the granulocytic, eosinophilic and mega-
karyocytic hyperplasia; megaloblastic changes were noticeable, espe-
cially in the erythroid compartment; dysplastic features were still
present, mainly involving the megakaryocytic lineage. Cytogenetic
analysis revealed no t(5;12) positive metaphase out of 30 analysed.
Biopsy of both erythematous and apparently normal skin showed
slight perivascular dermal infiltration by lymphoid cells. Immuno-
histochemical studies performed on these biopsy specimens showed
somewhat heavier infiltration by both CD4+ T cells (199 versus 100
cells/mm3) and eosinophils (5 vs. 0 cells/mm3) in the erythematous
areas. In contrast, no differences were observed in the number of
mast cells or in BCL-2 staining.
Discussion
We report the case of a 23-year-old man with CEL pre-
senting with atypical clinical features that led to a differ-
ential diagnosis with other conditions associated with
erythroderma, increased serum IgE and persistent eosino-
philia.
The fact that allergy could have explained a large pro-
portion of the initial clinical and laboratory findings
together with positive skin prick test for house dust mite
and a history of occupational exposure to metals led us to
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consider the possibility of a reactive eosinophilia second-
ary to a contact dermatitis. However, some of the clinical
and laboratory manifestations occurring during the initial
follow-up period, including the evidence of widespread
tissue infiltration by eosinophils, strongly argued against
this possibility. Two patients described by Keene et al.
[21] who had cytogenetic abnormalities involving 12p13
within eosinophils also proved to simultaneously have
schistosomiasis. The intriguing question is whether or not
a reactive process could have contributed to the develop-
ment of a clonal proliferation of eosinophils. It might be
speculated that in this patient an atopic tendency could,
by an unknown mechanism (e.g. cytokine production),
have been a predisposing factor to the myeloproliferative
disorder.
Erythroderma and increased serum IgE have both been
described in association with T-cell lymphomas and other
clonal T-cell disorders [22–28]. These conditions were
therefore considered in the differential diagnosis. How-
ever, T-cell clonality was excluded by both immunophe-
notypic analysis of peripheral blood lymphocytes and
molecular analysis of the TCR Vß repertoire and the
TCRß gene, respectively.
The clinical and laboratory findings in HES and CEL
overlap. In this case, cutaneous, ocular and immunologi-
cal manifestations suggested HES, whereas the occurrence
of organomegaly and the cytological features of the bone
marrow aspirate favoured the diagnosis of a myeloprolif-
erative disorder. The cytogenetic findings were essential
in establishing the diagnosis of CEL, by disclosing the
t(5;12)(q33;p13), a clonal marker which has previously
been reported in association with eosinophilic differentia-
tion in a myeloproliferative disorder. Despite this, the
immunophenotypic features of the peripheral blood eo-
sinophils present in this patient were identical to those
reported for normal peripheral blood eosinophils [29].
From the therapeutic point of view, the diagnosis of
CEL had important implications. Although there is no
consensus as to the best therapeutic approach, corticoste-
roids, hydroxyurea and interferon-alpha have been used
with variable success [10–12, 30, 31], complete remis-
sions being described with interferon therapy [12, 30]. In
the case herein reported, complete remission was not
achieved with any of these therapeutic strategies. How-
ever, there was a marked clinical and laboratory improve-
ment. This patient is now being considered for bone mar-
row transplantation in the hope of eliminating the leu-
kaemic clone and curing the disease.
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